On December 7, 2023 Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, reported that mutant RAS cancer vaccine TG01 adjuvanted by QS-21 STIMULON has passed the planned safety cohort review without any concerns in the multiple myeloma trial at Oslo University Hospital (OUS) (Press release, Circio, DEC 7, 2023, View Source [SID1234638233]). The study has now opened for full enrollment of twenty patients in total.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ola Melin, TG program lead of Circio Holding ASA, said: "This is the first time TG01 has been given to multiple myeloma patients, and the first formal safety review of TG01 administration with QS-21 STIMULON as adjuvant. As expected, there were no safety concerns reported, and we are very pleased that the study can now continue as planned. Dr. Schjesvold and his team have been very efficient to achieve this milestone rapidly, and we expect that the study will be fully enrolled during 2024."

In this phase 1 clinical trial, TG01 is being tested as a monotherapy in multiple myeloma in a clinical collaboration between OUS and Circio. The study is led by multiple myeloma expert Dr. Fredrik Schjesvold with OUS as the study sponsor. Circio provides TG01 drug supply, scientific support and a financial contribution.